Home / Deep Research / Autosomal Dominant Dopa-Responsive Dystonia

Autosomal Dominant Dopa-Responsive Dystonia

Autosomal Dominant Dopa-Responsive Dystonia Deep Research Fallback

⚠️ Fallback MONDO:0971063

Autosomal Dominant Dopa-Responsive Dystonia Deep Research Fallback

Provider Attempts

  • falcon: just research-disorder falcon Autosomal_Dominant_Dopa_Responsive_Dystonia started and remained silent for more than one minute; terminated with signal 15.
  • openai: just research-disorder openai Autosomal_Dominant_Dopa_Responsive_Dystonia started and remained silent for more than one minute; terminated with signal 15.

Because the providers did not return a usable report, curation proceeded from generated Orphanet ORPHA:98808 and a bounded set of fetched PubMed/DOI references.

Integrated Literature Synthesis

Autosomal dominant dopa-responsive dystonia is a rare neurometabolic disorder with childhood-onset dystonia, frequent parkinsonism and extrapyramidal motor features, and a characteristic dramatic response to low-dose levodopa. Orphanet lists the disease as MONDO:0971063 / ORPHA:98808 and provides the definition, European point prevalence, disease genes, and frequent HPO phenotypes.

The canonical mechanism is GCH1 deficiency. Human family studies identify GCH1, encoding GTP cyclohydrolase I, as the first causative gene for dopa-responsive dystonia. GeneReviews states that diagnosis is established by a heterozygous pathogenic variant in GCH1 and that the disorder is autosomal dominant with reduced penetrance. Mechanistically, GCH1 affects tetrahydrobiopterin biosynthesis; human cohort evidence links DRD to genes encoding enzymes involved in dopamine and tetrahydrobiopterin biosynthesis. This supports a graph from GCH1 enzymatic deficiency to impaired striatal dopamine biosynthesis and downstream dystonia/parkinsonism.

Rarer genes were represented because they are listed directly in ORPHA:98808. IMPDH2 evidence comes from a dominantly inherited Finnish dystonia-tremor family with a heterozygous truncating variant and patient-cell evidence of IMPDH2 deficiency. NR4A2 evidence comes from two patients with loss-of-function variants, dystonia parkinsonism, and DATscan evidence of bilateral dopaminergic denervation.

Treatment evidence centers on levodopa. GeneReviews describes immediate to near-term motor benefit and complete or near-complete responsiveness at low daily doses of levodopa/decarboxylase inhibitor, with chronic levodopa motor complications typically absent. Orphanet defines the disorder by dramatic and sustained low-dose levodopa response.

Key References

  • ORPHA:98808 - Orphanet structured record for definition, phenotype frequencies, gene rows, cross-references, and prevalence.
  • PMID:20301681 - GeneReviews for GCH1 diagnosis, clinical characteristics, inheritance, and levodopa management.
  • PMID:8852666 - Human family evidence identifying GCH1/GTPCH as a causative gene for dopa-responsive dystonia.
  • PMID:28087438 - Human DRD cohort linking dopamine and tetrahydrobiopterin biosynthesis genes to disease mechanism.
  • PMID:33875303 - Early-onset AD GCH1 deficiency case series/meta-analysis with gait disturbance, diurnal fluctuation, diagnostic delay, residual signs, and levodopa treatment relevance.
  • PMID:31922365 - NR4A2 loss-of-function dystonia-parkinsonism cases with dopaminergic denervation.
  • DOI:10.1038/s41431-021-00939-1 - IMPDH2 truncating variant, patient-cell deficiency, and guanine metabolism/dopamine synthesis link.